Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7-8
pubmed:dateCreated
2007-9-10
pubmed:abstractText
Apert syndrome (AS), a severe form of craniosynostosis, is caused by dominant gain-of-function mutations in FGFR2. Because the periosteum contribution to AS cranial pathophysiology is unknown, we tested the osteogenic potential of AS periosteal cells (p.Ser252Trp mutation) and observed that these cells are more committed toward the osteoblast lineage. To delineate the gene expression profile involved in this abnormal behavior, we performed a global gene expression analysis of coronal suture periosteal cells from seven AS patients (p.Ser252Trp), and matched controls. We identified 263 genes with significantly altered expression in AS samples (118 upregulated, 145 downregulated; SNR >or= |0.4|, P <or= 0.05). Several upregulated genes are involved in positive regulation of cell proliferation and nucleotide metabolism, whereas several downregulated genes are involved in inhibition of cell proliferation, gene expression regulation, cell adhesion, and extracellular matrix organization, and in PIK3-MAPK cascades. AS expression profile was confirmed through real-time PCR of a selected set of genes using RNAs from AS and control cells as well as from control cells treated with high FGF2 concentration, and through the analysis of genes involved in FGF-FGFR signaling. Our results allowed us to: (a) suggest that AS periosteal cells present enhanced osteogenic potential, (b) unravel a specific gene expression signature characteristic of AS periosteal cells which may be associated with their osteogenic commitment, (c) identify a set of novel genes involved in the pathophysiology of AS or other craniosynostotic conditions, and (d) suggest for the first time that the periosteum might be involved in the pathophysiology of AS.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-10521349, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-10739663, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-10851026, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-11121055, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-11214061, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-11304456, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-11315998, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-11823860, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-12454644, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-12477974, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-1303629, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-14499350, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-15096041, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-15166289, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-15221013, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-15781477, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-15975938, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-16644866, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-17164422, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-7668257, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-7719344, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-8651276, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-8673103, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-9041375, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-9502772, http://linkedlifedata.com/resource/pubmed/commentcorrection/17622301-9700203
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1076-1551
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
422-42
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:17622301-Acrocephalosyndactylia, pubmed-meshheading:17622301-Adolescent, pubmed-meshheading:17622301-Amino Acid Substitution, pubmed-meshheading:17622301-Cell Differentiation, pubmed-meshheading:17622301-Cell Lineage, pubmed-meshheading:17622301-Child, pubmed-meshheading:17622301-Child, Preschool, pubmed-meshheading:17622301-Female, pubmed-meshheading:17622301-Fibroblasts, pubmed-meshheading:17622301-Gene Expression, pubmed-meshheading:17622301-Gene Expression Profiling, pubmed-meshheading:17622301-Gene Expression Regulation, Developmental, pubmed-meshheading:17622301-Humans, pubmed-meshheading:17622301-Infant, pubmed-meshheading:17622301-Male, pubmed-meshheading:17622301-Mutation, pubmed-meshheading:17622301-Oligonucleotide Array Sequence Analysis, pubmed-meshheading:17622301-Osteogenesis, pubmed-meshheading:17622301-Periosteum, pubmed-meshheading:17622301-Receptor, Fibroblast Growth Factor, Type 2, pubmed-meshheading:17622301-Serine, pubmed-meshheading:17622301-Skull, pubmed-meshheading:17622301-Tryptophan
pubmed:articleTitle
Apert p.Ser252Trp mutation in FGFR2 alters osteogenic potential and gene expression of cranial periosteal cells.
pubmed:affiliation
Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, Brazil.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't